. Author manuscript; available in PMC: 2020 Apr 19.

Published in final edited form as: ACS Infect Dis. 2019 Sep 18;5(11):1952–1962. doi: 10.1021/acsinfecdis.9b00284

Table 1.

Antiviral efficacy and cellular cytotoxicity of R856932 against EV-D68 and EV-A71 in RD cells.^a

Viruses	R856932 CC₅₀ = 32.0 ± 3.4 (μM)		Pleconaril CC₅₀ = 14.1 ± 4.1 (μM)		Telaprevir CC₅₀ = 46.2 ± 14.3 (μM)
Viruses	EC₅₀ (μM)	SI	EC₅₀ (μM)	SI	EC₅₀ (μM)	SI
EV-D68 US/MO/14–18947 (clade B1)	0.46 ± 0.09	70	0.03 ± 0.01	470	0.86 ± 0.07	54
EV-D68 US/MO/14–18949 (clade B1)	1.40 ± 0.04	22.9	0.15 ± 0.01	94	0.50 ± 0.04	92
EV-D68 US/IL/14–18952 (clade B2)	4.39 ± 0.21	7.29	0.14 ± 0.03	101	1.54 ± 0.07	30.0
EV-D68 US/IL/14–18956 (clade B2)	1.77 ± 0.05	18.1	0.19 ± 0.02	74	0.44 ± 0.00	105
EV-D68 US/KY/14–18953 (clade D)	3.34 ± 0.31	9.58	0.09 ± 0.02	157	0.39 ± 0.05	118
EV-A71 Tainan/4643/1998	>50	N.A.	>5	N.A.	>15	N.A.
EV-A71 MP4	>50	N.A.	>5	N.A.	>15	N.A.

The EC₅₀ values of different strains of EV-D68 and EV-A71 in RD cells were determined using a cytopathic effect (CPE) assay. The CC₅₀ values were determined by a CPE assay in RD cells after 3 days of drug incubation. EC₅₀ = mean ± standard deviation. SI: Selection Index; N.A.: Not Available; The values are the mean ± standard deviation from three replicates.